Wyeth Initiates INTORACT — A New Clinical Trial To Examine TORISEL Plus Avastin For First-Line Treatment Of Advanced Kidney Cancer

May 31st, 2008 | Category: Cancer

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the initiation of the INTORACT (INvestigation of TORISEL and Avastin Combination Therapy) study, a worldwide randomized, open-label, phase 3b study comparing TORISEL(R) (temsirolimus)

plus Avastin(R) (bevacizumab) versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma (RCC).

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Wyeth’s TORISEL Receives European Commission Approval For The Treatment Of Advanced Kidney Cancer
  • Avastin Receives Positive Opinion In Europe For First-line Treatment Of Patients With Advanced Kidney Cancer
  • Avastin Approved In Europe For First-Line Treatment Of Patients With Advanced Kidney Cancer
  • European Committee Issues Positive Opinion On Wyeth’s TORISEL For Advanced Renal Cell Carcinoma
  • New Breakthrough Treatment For Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.